Literature DB >> 14704831

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.

P G Penketh1, K Shyam, R P Baumann, J S Remack, T P Brent, A C Sartorelli.   

Abstract

PURPOSE: To investigate the interaction of the electrophilic species generated by the decomposition of the antineoplastic prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M) on the ability of O(6)-alkylguanine-DNA alkyltransferase (AGT) to repair alkylated O(6)-chloroethylguanine and/or N(1),O(6)-ethanoguanine DNA lesions.
MATERIALS AND METHODS: The contributions of inhibitory electrophilic species generated from VNP40101M towards AGT was assessed using analogues that selectively generated either the chloroethylating or the carbamoylating components of VNP40101M. The activity of AGT was determined from the inhibition of crosslink formation from O(6)-chloroethylguanine and/or N(1),O(6)-ethanoguanine lesions. The half-lives of sulfonylhydrazine derivatives and isocyanates were measured using an acidification assay which gives a change in absorbance proportional to the release or consumption of small quantities of protons.
RESULTS: Both of the reactive components produced by VNP40101M directly inactivated cloned human AGT; the carbamoylating moiety (IC(50) about 13 micro M) was approximately seven- to eight-fold more potent than the alkylating component(s) (IC(50) about 100 micro M). These inhibitory actions were moderated by the addition of naked T5 bacteriophage DNA. Thus, AGT bound to DNA was markedly more resistant than free AGT to these electrophilic species. DNA also blocked the spontaneous loss of AGT activity which occurred upon incubation of this protein under mild conditions.
CONCLUSIONS: The reaction of AGT with the methyl isocyanate generated from the decomposition of VNP40101M increased the net number of crosslinks generated by VNP40101M compared to a sulfonylhydrazine prodrug that formed the equivalent alkylating species in the absence of the cogeneration of methyl isocyanate. These actions may be of significance to the antineoplastic activity of VNP40101M.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14704831     DOI: 10.1007/s00280-003-0740-7

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.

Authors:  Rui Zhu; Mao-Chin Liu; Mei-Zhen Luo; Philip G Penketh; Raymond P Baumann; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  J Med Chem       Date:  2011-10-17       Impact factor: 7.446

2.  pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugs.

Authors:  Philip G Penketh; Richard A Finch; Rachel Sauro; Raymond P Baumann; Elena S Ratner; Krishnamurthy Shyam
Journal:  Chem Biol Drug Des       Date:  2017-07-17       Impact factor: 2.817

3.  1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells.

Authors:  Helen A Seow; Philip G Penketh; Krishnamurthy Shyam; Sara Rockwell; Alan C Sartorelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-17       Impact factor: 11.205

4.  Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.

Authors:  Kimiko Ishiguro; Helen A Seow; Philip G Penketh; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

5.  Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.

Authors:  Sara Rockwell; Yanfeng Liu; Helen A Seow; Kimiko Ishiguro; Raymond P Baumann; Philip G Penketh; Krishnamurthy Shyam; Oluwatoyin M Akintujoye; Peter M Glazer; Alan C Sartorelli
Journal:  Int J Radiat Biol       Date:  2011-12-20       Impact factor: 2.694

6.  Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase.

Authors:  Rui Zhu; Helen A Seow; Raymond P Baumann; Kimiko Ishiguro; Philip G Penketh; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  Bioorg Med Chem Lett       Date:  2012-08-10       Impact factor: 2.823

7.  Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.

Authors:  Kimiko Ishiguro; Yong-Lian Zhu; Krishnamurthy Shyam; Philip G Penketh; Raymond P Baumann; Alan C Sartorelli
Journal:  Biochem Pharmacol       Date:  2010-07-21       Impact factor: 5.858

8.  A strategy for selective O(6)-alkylguanine-DNA alkyltransferase depletion under hypoxic conditions.

Authors:  Philip G Penketh; Krishnamurthy Shyam; Raymond P Baumann; Kimiko Ishiguro; Eric V Patridge; Rui Zhu; Alan C Sartorelli
Journal:  Chem Biol Drug Des       Date:  2012-05-23       Impact factor: 2.817

9.  Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanine.

Authors:  Rui Zhu; Raymond P Baumann; Philip G Penketh; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  J Med Chem       Date:  2013-01-23       Impact factor: 7.446

10.  Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species.

Authors:  Philip G Penketh; Raymond P Baumann; Kimiko Ishiguro; Krishnamurthy Shyam; Helen A Seow; Alan C Sartorelli
Journal:  Leuk Res       Date:  2008-05-13       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.